Translatable Efficacy & Safety Testing of mAb, Bispecific, & CAR T Therapies
During this webinar, we discuss preclinical data showcasing efficacy and safety testing of immunotherapies in immune humanized mouse models.
Watch Video
With JAX’s Cytokine Release Syndrome (CRS) evaluation platform, you can move to an IND filing with more confidence about the safety of your therapeutic prior to entering clinical trials. With our novel humanized mouse platform, you can test candidate therapeutics in the presence of tumor, multiple donors, and multiple doses, testing for both immunotoxicity and drug efficacy in the same study.
During this webinar, we discuss preclinical data showcasing efficacy and safety testing of immunotherapies in immune humanized mouse models.
Watch Video
Learn about Hu-PBMC NSG models that can be used to test the efficacy of human T cell immunomodulatory therapeutics for graft-versus-host disease (GvHD), autoimmune disorders, and cancer.
Watch Video
In this special joint webinar, we discuss CAR T-induced Immunotoxicity, highlighting cutting-edge platforms for assessing the safety and efficacy of CAR therapies and preventing the development of CRS
Watch Video
In this special joint webinar, we discuss CAR T-induced Immunotoxicity, highlighting cutting-edge platforms for assessing the safety and efficacy of CAR therapies and preventing the development of CRS
Watch Video
Read Flipbook
JAX NSG-MHC I/II KO mice readily engraft tumors and human PBMCs, have delayed GvHD, and deliver translationally-relevant results for various research applications.
Read Flipbook
A study developed PBMC-engrafted NSG mouse models to assess CRS in vivo, demonstrating that these models are rapid, sensitive, and reproducible platforms for screening novel therapeutics for CRS.
Read Flipbook
Review JAX’s CRS evaluation capabilities and see how a CRS study can help move your CAR T therapeutic into the clinic faster, safer, and more confidently.
Read Flipbook
A glimpse at the wide range of platforms and services JAX offers to help move you from drug discovery to IND filing.
Read Flipbook
Although many mammals have immune systems that share important characteristics with humans, certain immune cell types and phenomena are unique to us. As a result, it has been difficult to design...
Learn More
Brian W. Soper, Ph.D. speaks about the efficacy and safety of therapeutics in immuno-modulatory induced cytokine release syndrome. Dr. Soper discusses human PBMC engraftment profiles; modeling human c
Watch Video
In vivo CRS assays have the potential to simultaneously derisk and accelerate the process of bringing successful therapies to the patients who need them most.
Read Flipbook
Dr. James Keck, Senior Director, Innovation and Product Development, The Jackson Laboratory, presents De-risking Therapeutic Antibody Preclinical Drug Development: Simultaneous Assessment of Efficacy
Watch Video
Dr. Danyig Cai, Associate Director, Innovation & Product Development, The Jackson Laboratory, presents An In Vivo PBMC Humanized Mouse Model for Determining Immunotherapy Related Cytokine Release Synd
Watch Video
Immunomodulatory Induced Cytokine Release; What In Vivo Tells You That In Vitro Cannot
Watch Video
Alba Matas Céspedes, Astra Zeneca Title: Use of human splenocytes in an innovative humanized mouse model for prediction of immunotherapy-inducedcytokine release syndrome
Watch Video
Join Rick Huntress and Dr. Basile Siewe on Wednesday, August 19 for the next episode of JAXLive! where they will discuss an in vivo CRS platform with both efficacy and safety applications.
Watch Video
Read Flipbook
This whitepaper examines the constraints and challenges inherent in each CAR T study type and how to overcome them with in vivo studies using fully humanized mouse models.
Read Flipbook